ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 708

Development of Spondyloarthritis-Features in Patients with Chronic Back Pain over a One-Year Course: Data from the Spondyloarthritis Caught Early (SPACE)-Cohort

Zineb Ez-Zaitouni1, Miranda van Lunteren1, Pauline Bakker1, Inger Jorid Berg2, Robert Landewé3, Maikel van Oosterhout4, Augusta Ortolan5, Désirée van der Heijde1 and Floris van Gaalen1, 1Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 3Clinical Immunology and Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, 4Rheumatology, Groene Hart Hospital, Gouda, Netherlands, 5Rheumatology Unit, Department of Medicine DIMED, Rheumatology Unit,University of Padova, Padova, Italy

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: chronic low back pain, classification criteria, diagnosis and spondylarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2016

Title: Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster I: Axial and Peripheral Spondyloarthritis – Clinical Aspects, Imaging and Treatment

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Little is known on the development of spondyloarthritis (SpA)-features over time in patients with recent onset chronic back pain (CBP). The aim was to explore whether patients with suspicion of axial spondyloarthritis (axSpA) develop SpA-features over time in the SPACE-cohort, and to study the effect of gaining features on the clinical diagnosis and classification according to the Assessment of SpondyloArthritis international Society (ASAS)-criteria for axSpA.

Methods: SPACE is an inception cohort study in which CBP patients ( ≥ 3 months, ≤ 2 years, onset < 45 years) from various rheumatology centres across Europe are included. Baseline (BL) and one-year (FU) data were used for this study. Patients underwent a full diagnostic work-up consisting of MRI and radiographs of the sacroiliac joints (MRI-SI and X-SI), acute phase reactants, HLA-B27, and assessment of all other SpA-features. For the purpose of this study positive SpA-features were accumulated according to the principle of “once a feature always a feature” meaning patients were not able to ‘lose’ features over time. Total number of SpA-features was calculated excluding sacroiliac imaging and HLA-B27 status. Clinical diagnosis (axSpA yes/no) of patients was provided by the treating rheumatologist with use of local reading and the ASAS-criteria for axSpA (based on central scoring and agreement of 2/3 readers) were used for classification.

Results: A total of 270 patients with CBP with both baseline and one-year follow-up visits were included: 36.7% were male, mean age (SD) at inclusion was 31.2 (8.0) years, mean number of SpA-features (SD) at BL and one-year FU were 2.8 (1.5) and 3.5 (1.6), respectively. After one year 49.3% of patients had gained one or more features. Most common features were IBP (BL: 77.0%, FU: 88.2%), good response to NSAIDs (BL: 48.5%, FU: 70.6%), elevated CRP/ESR (BL: 29.5%, FU: 43.3%), and positive family history for SpA (BL: 48.9%, FU: 52.6%). For 16 out of the 270 patients information on diagnosis at either BL or FU was missing. In the remaining 254 patients, rheumatologists diagnosed 150 (59.1%) and 66 (26.0%) patients with axSpA and no axSpA at both time points, respectively (Figure 1). In 15.0% (38/254) of patients the diagnosis changed; 16 patients with no axSpA diagnosis at BL were diagnosed with axSpA at FU of which 11/16 (68.8%) had acquired one or more features. In 22 patients with axSpA at BL rheumatologists reconsidered their diagnosis at FU. In the 150 patients diagnosed with axSpA, 108/150 (72%) of patients already fulfilled the ASAS-criteria at BL and 79/150 (52.7%) patients gained a minimum of one feature, which led to a new axSpA classification for 9 patients at FU.

Conclusion: In patients with CBP of short duration almost half developed at least one new SpA-feature within one year, however the impact on diagnosis and classification was limited.


Disclosure: Z. Ez-Zaitouni, None; M. van Lunteren, None; P. Bakker, None; I. J. Berg, None; R. Landewé, None; M. van Oosterhout, None; A. Ortolan, None; D. van der Heijde, None; F. van Gaalen, None.

To cite this abstract in AMA style:

Ez-Zaitouni Z, van Lunteren M, Bakker P, Berg IJ, Landewé R, van Oosterhout M, Ortolan A, van der Heijde D, van Gaalen F. Development of Spondyloarthritis-Features in Patients with Chronic Back Pain over a One-Year Course: Data from the Spondyloarthritis Caught Early (SPACE)-Cohort [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/development-of-spondyloarthritis-features-in-patients-with-chronic-back-pain-over-a-one-year-course-data-from-the-spondyloarthritis-caught-early-space-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/development-of-spondyloarthritis-features-in-patients-with-chronic-back-pain-over-a-one-year-course-data-from-the-spondyloarthritis-caught-early-space-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology